FDA advisory panel gives nod to ticagrelor for use in acute coronary syndrome
The Cardiovascular and Renal Drugs Advisory Committee
voted 7-1 to recommend approval of the use of ticagrelor for the reduction of
thrombotic events in patients with acute coronary syndromes.
FULL STORY